{"filings":[{"id":91365,"accession_number":"0001193125-26-208912","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.","20 Light Delivery Devices sold in Q1, expanding installed base to 1,154 units.","Net loss of $(15.9)M ($(0.38)/share) vs $(8.2)M ($(0.20)/share) in Q1 2025.","Cash, equivalents and short-term investments totaled $217.9M as of March 31, 2026.","2026 revenue guidance reiterated at $120M-$135M; gross margin 70%-72%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":30893000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101390,"accession_number":"0001193125-26-115965","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K/A","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight discloses CFO's sign-on bonus of $169K and corrects option vesting schedule","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mark Wilterding's sign-on bonus determined at $169,348.10 and paid March 13, 2026.","Sign-on bonus paid less payroll deductions and required withholding, per employment letter.","Option vesting corrected: 25% vests on Jan 11, 2027 anniversary, balance monthly over next 3 years.","Option fully vested after 4 years from Jan 11, 2026, subject to continued employment.","Amendment filed to prior 8-K dated Jan 12, 2026 regarding CFO appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101392,"accession_number":"0001193125-26-071516","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.","FY 2025 revenue $134.5M (-4% YoY); net loss $(38.9M) vs $(27.5M) in 2024.","LAL unit sales 109,615 (+12% YoY); LDD installed base 1,134 units; procedures >300,000 since launch.","FY 2026 guidance: revenue $120-135M (down YoY); gross margin 70-72%; op-ex $150-160M.","Adjusted net loss per share $(0.18) in FY 2025 vs $(0.07) in FY 2024; cash $228.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":134479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101391,"accession_number":"0001193125-26-010478","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.","LAL procedure volume 28,611 in Q4 (+10% QoQ) and 109,615 in FY2025 (+12% YoY).","Installed LDD base reached 1,134 as of Dec 31, 2025 (25 LDDs sold in Q4).","Cash & short-term investments ~$228.1M as of Dec 31, 2025.","Mark Wilterding appointed CFO effective Jan 11, 2026, replacing Shelley Thunen (consulting role)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":134479000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117755,"accession_number":"0001193125-25-331151","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RxSight enters CFO transition agreement with Thunen; reaffirms 2025 outlook","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shelley Thunen transitions from CFO; transition and consulting agreements executed effective Dec 23, 2025.","Company reaffirms full-year 2025 outlook unchanged by CFO transition.","Transition was previously announced; material terms incorporated by reference from Dec 22, 2025 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117754,"accession_number":"0001193125-25-328951","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.","Consulting agreement provides $15,000 monthly retainers for Jan-Mar 2026, plus $500/hour for services.","Thunen remains eligible for fiscal 2025 annual cash bonus based on corporate performance.","Outstanding stock options continue vesting during consulting term ending Dec 31, 2026.","No successor named; Ron Kurtz cites nearly decade of service; company has 1,100+ LDDs and 250k+ procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117753,"accession_number":"0001193125-25-326889","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight appoints Eric Weinberg as Chief Business Development Officer, Scott Gaines as Chief Customer Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Weinberg appointed Chief Business Development Officer, transitioning from Chief Commercial Officer on December 18, 2025.","Scott Gaines appointed Chief Customer Officer, overseeing Company's U.S. commercial organization.","Both appointments effective December 18, 2025, per Board decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117752,"accession_number":"0001193125-25-266938","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.","Net loss $(9.8)M ($(0.24)/share) vs $(6.3)M ($(0.16)/share) in Q3 2024.","Adjusted net loss $(1.7)M ($(0.04)/share) vs adjusted net gain $0.2M prior year.","Narrowed FY2025 revenue guidance to $125-130M (prior $120-130M); raised gross margin guidance to 76-77%.","Cash and investments $227.5M, unchanged from June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":101871000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134194,"accession_number":"0001111485-25-000003","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K/A","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RxSight appoints director Cohen to Compensation and Audit Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond W. Cohen appointed to Compensation and Audit Committees effective August 14, 2025.","Compensation Committee now: Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, Raymond W. Cohen.","Audit Committee now: Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D, Raymond W. Cohen.","This amendment updates the July 31, 2025 8-K that reported Cohen's Board appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134197,"accession_number":"0000950170-25-105027","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.","Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.","Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.","Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.","Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":71531000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134196,"accession_number":"0000950170-25-102065","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RxSight appoints former Axonics CEO Raymond Cohen to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.","Cohen also led SoniVie sale to Boston Scientific for $600M; has over 40 years medtech experience.","Will serve until 2028 annual meeting; receives standard non-employee director compensation including $277,500 initial RSU grant.","Press release issued August 4, 2025; no other changes to board or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134195,"accession_number":"0000950170-25-094588","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.","FY2025 revenue guidance slashed to $120-130M (from $160-175M), implying 7-14% decrease from 2024.","Gross margin guidance raised to 72-74% (from 71-73%); operating expense guidance $145-155M, up 7-14% YoY.","Installed LDD base of 1,084 units (+34% YoY); management cites underperformance and plans to refocus commercial strategy.","Cash $227.5M as of June 30, 2025, down $1.8M from March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":71531000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150973,"accession_number":"0000950170-25-081636","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight shareholders re-elect three Class I directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of ~79.2% (32.18M of 40.62M shares represented) at June 3 annual meeting.","Ron Kurtz, J. Andy Corley, and Juliet Tammenoms Bakker re-elected as Class I directors.","Say-on-pay advisory vote passed with 22.37M for, 3.32M against, 98.7K abstain.","Ratification of Ernst & Young as auditor for FY2025 approved with 31.95M for, 92K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150972,"accession_number":"0000950170-25-065655","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.","Net loss $(8.2M) or $(0.20)/share; adjusted net loss $(1.1M) or $(0.03)/share.","27,579 LALs sold (+36% YoY); 73 LDDs; installed base 1,044 (+43% YoY).","Gross margin 74.8% vs 70.1% YoY; cash $229.3M at quarter end.","Reiterated FY2025 guidance: revenue $160-175M, GM 71-73%, OpEx $150-160M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":37895000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150971,"accession_number":"0000950170-25-049797","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).","LDD installed base reached 1,044 as of March 31, 2025, a 43% increase from 732 a year earlier.","FY2025 revenue guidance lowered to $160M-$175M (from $185M-$197M); operating expense guidance cut to $150M-$160M.","Stock-based compensation expected to be $27M-$30M, up from prior $22M-$25M; cites premium IOL market headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":37895000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169877,"accession_number":"0000950170-25-026651","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).","Q4 net loss $(5.9)M vs $(9.2)M; adjusted net earnings $1.3M ($0.03/share) vs adjusted loss $(4.8M).","LAL procedure volume 29,069 units (+61% YoY); LDD installed base 971 (+46% YoY).","FY2025 guidance: revenue $185-197M (32-41% growth), gross margin 71-73%, operating expenses $165-170M.","Cash and investments $237.2M; no debt mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":139927000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169876,"accession_number":"0000950170-25-004478","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).","LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).","LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.","2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.","Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":139927000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186929,"accession_number":"0000950170-24-123322","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).","Gross margin 71.4% vs 61.9% YoY; net loss narrowed to $6.3M ($0.16/sh) from $12.4M ($0.35/sh).","Adjusted net earnings $214K ($0.00/diluted) vs adjusted loss $6.9M ($0.19/sh) a year ago.","FY2024 revenue guidance raised to $139-140M top of prior range; gross margin guided 70-71% (up from 68-70%).","Cash & equivalents $237.1M at Sept 30, 2024 vs $233.3M at June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":99713000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203470,"accession_number":"0000950170-24-090744","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.","Net loss improved to $(6.1)M ($(0.16)/share) from $(13.8)M ($(0.40)/share) in Q2 2023; adjusted net income $0.0M.","Installed LDD base reached 810 units (+55% YoY); 78 LDDs sold in Q2 (+16% YoY).","FY2024 revenue guidance raised to $139-140M (56-57% growth) from prior $132-137M; gross margin guidance unchanged 68-70%.","Cash $233.3M at June 30, 2024, includes $107.5M net proceeds from public offering closed May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":64399000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219907,"accession_number":"0000950170-24-069895","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"RxSight shareholders re-elect three Class III directors, approve say-on-pay, one-year frequency, and E&Y ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors re-elected: Julie B. Andrews, Robert J. Palmisano, Tamara R. Fountain.","Say-on-pay approved: 22.6M for, 1.1M against, 0.4M abstain.","Advisory vote on frequency: one-year option favored with 20.5M votes; company will hold annual say-on-pay.","Ratification of Ernst & Young as independent auditor for FY 2024: 29.9M for, 46k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219906,"accession_number":"0001193125-24-135328","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"RxSight prices $100M public stock offering at $56/share for commercial expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.","Net proceeds expected ~$93.2M after underwriting discount and estimated offering expenses.","Proceeds to fund commercial/marketing expansion (including international), product development, R&D, and working capital.","Offering expected to close May 13, 2024, subject to customary closing conditions.","Directors and executive officers subject to 60-day lock-up restrictions on their shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219905,"accession_number":"0000950170-24-053553","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).","Gross margin expands to 70% from 59% on favorable mix and lower production costs.","Net loss narrows to $9.1M ($0.25/share) from $13.2M ($0.42); adjusted loss $4.4M ($0.12).","Raises FY2024 revenue guidance to $132-137M (from $128-135M) and gross margin to 68-70%.","Cash remains strong at $125.4M, down slightly from $127.2M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":29512000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219904,"accession_number":"0000950170-24-046558","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"RxSight enters new lease and amends two leases for Aliso Viejo facilities with ~$10.8M future minimum payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New 26,825 sq ft lease at 125 Columbia: base rent $41,579/mo, term June 1, 2024–Jan 31, 2031, with two 60-month renewal options.","Amended 5 Columbia lease: extended 70 months from April 2025; base rent $30,701/mo with escalations from April 2027.","Amended 100 Columbia lease: extended 76 months from Oct 2024; base rent $64,843/mo with escalations from Oct 2025.","Future minimum lease payments total ~$10.8M: $0.2M in 2024, $1.4M in 2025, $1.6M in 2026, $1.8M in 2027/2028, $4.0M thereafter.","Leases align end dates to Jan 2031 across four facilities and add manufacturing capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239655,"accession_number":"0000950170-24-022053","cik":1111485,"company_name":"RxSight, Inc.","ticker":"RXST","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).","Full year 2023 revenue $89.1M (+82% YoY); net loss $(48.6)M vs $(66.8)M in 2022.","Q4 gross margin 62% vs 46% YoY; full year gross margin 60% vs 44%.","FY2024 guidance: revenue $128M-$135M (44-52% growth); gross margin 65-67%; opex $125M-$128M.","Cash and investments $127.2M at Dec 31; Q4 adjusted net loss $(4.8)M or $(0.13)/share."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":89077000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232648940.78798,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}